Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Naloxone dosing

The initial dose of buprenorphine should be given at least 12-24 hours after the last heroin dose, 24 hours after the last methadone dose, or 48 hours after the last LAAM dose (see Table 2-3). The methadone dosage of methadone maintenance patients should be reduced to 30 mg/day before the transfer to buprenorphine is attempted. Ideally patients should show clear evidence of opiate withdrawal before receiving the first dose of buprenorphine, to avoid the risk that buprenorphine will precipitate more severe withdrawal. For the first day, sublingual buprenorphine/naloxone doses of 2/0.5-4/1 mg can be given every 2-4 hours, up to a maximum total dose of 8/2 mg/day. On the... [Pg.81]

Dose amounts consist of the buprenorphine dose (the number before the slash) and the naloxone dose (the number after the slash). Do not begin buprenorphine until patient shows evidence of opioid withdrawal. [Pg.82]

Heishman SJ, Stitzer ML, Bigelow GE, et al Acute opioid physical dependence in postaddict humans naloxone dose effects after brief morphine exposure. J Pharmacol Exp Ther 248 127-134, 1989... [Pg.100]

Respiratory Buprenorphine-induced respiratory depression has been studied in 24 subjects who received buprenorphine 0.2 mg and increasing doses of naloxone [184 ]. Reversal of buprenorphine-induced respiratory depression required high doses of naloxone (over 2 mg) and further increases in naloxone dose (to over 4 mg) resulted in recurrent respiratory depression. [Pg.225]

Zipeprol [34758-83-3] (58) is another European antitussive with a wide range of pharmacological effects, including antispasmodic, antihistaminic, and local anesthetic activities (85,86). It has been reported that zipeprol has been abused in Italy because high doses cause hallucinations (87). Spontaneous withdrawal symptoms similar to those of opiates have been observed withdrawal symptoms can also be precipitated by naloxone. Zipeprol can be... [Pg.525]

The effects of some narcotics may last longer than the effects of naloxone. A repeat dose of naloxone may be ordered by the primary health care provider if results obtained from the initial dose are unsatisfactory. The duration of close patient observation depends on the patient s response to the administration of the narcotic antagonist. [Pg.182]

Personality variables, state of mind at time of withdrawal, and expectations of severity of symptoms all may affect withdrawal severity (Kleber 1981). One study found that merely providing addicts information about the withdrawal syndrome resulted in lower levels of withdrawal symptoms (Green and Gos-sop 1988). Naloxone rapidly induces a severe withdrawal syndrome, which peaks within 30 minutes and then declines rapidly. Until the antagonist is eliminated, only partial suppression of the withdrawal syndrome is possible, and then only by using very high opioid doses, which may cause respiratory depression when naloxone is metabolized. [Pg.71]

The approval of buprenorphine for the office-based treatment of opioid dependence represents a major departure from the earlier methadone clinic system. Physicians with addiction specialist credentials or those who have completed 8 hours of approved training can become qualified to treat up to 30 patients in their private offices. Stable patients may be given prescriptions for up to a month of medication. The combination buprenorphine/naloxone tablet is expected to have minimal risk for diversion. When taken subhnguaUy, as prescribed, naloxone has minimal biologic activity and does not interfere with the buprenorphine dose. However, if an attempt is made to inject the drug, the addict will experience the full antagonist effect of the naloxone. [Pg.83]

Yaksh TL, Rudy TA (1977) A dose ratio comparison of the interaction between morphine and cyclazocine with naloxone in rhesus monkeys on the shock titration task. Eur J Pharmacol 46(2) 83-92... [Pg.352]

Since large doses of naloxone (10 and 50 m/kg) did not antagonize the ability of PCP or cyclazocine to induce stereotyped behavior... [Pg.96]

Epidural analgesia is frequently used for lower extremity procedures and pain (e.g., knee surgery, labor pain, and some abdominal procedures). Intermittent bolus or continuous infusion of preservative-free opioids (morphine, hydromorphone, or fentanyl) and local anesthetics (bupivacaine) may be used for epidural analgesia. Opiates given by this route may cause pruritus that is relieved by naloxone. Adverse effects including respiratory depression, hypotension, and urinary retention may occur. When epidural routes are used in narcotic-dependent patients, systemic analgesics must also be used to prevent withdrawal since the opioid is not absorbed and remains in the epidural space. Doses of opioids used in epidural analgesia are 10 times less than intravenous doses, and intrathecal doses are 10 times less than epidural doses (i.e., 10 mg of IV morphine is equivalent to 1 mg epidural morphine and 0.1 mg of intrathecally administered morphine).45... [Pg.497]

Patients who are acutely intoxicated with an opioid usually present with miosis, euphoria, slow breathing and slow heart rate, low blood pressure, and constipation. Seizures may occur with certain agents such as meperidine (Demerol ). It is critically important to monitor patients carefully to avoid cardiac/ respiratory depression and death from an excessive dose of opioids. One strategy is to reverse the intoxication by utilizing naloxone (Narcan ) 0.4 to 2 mg IV every 2 to 3 minutes up to 10 mg. Alternatively, the IM/SC route may be used if IV access is not available. Because naloxone is shorter-acting than most abused opioids, it may need to be readministered at periodic intervals otherwise the patient could lapse into cardiopulmonary arrest after a symptom-free interval of reversed... [Pg.532]

If neither IV nor IO access can be established, atropine, lidocaine, epinephrine, naloxone, and vasopressin may be administered endotracheally. The endotracheal dose should generally be two to two and one-half times larger than the IV/IO dose. [Pg.90]

Respiratory depression increases progressively as doses are increased. It often manifests as a decrease in respiratory rate, and the cough reflex is also depressed. Patients with underlying pulmonary dysfunction are at risk for increased respiratory compromise. Respiratory depression can be reversed by naloxone. [Pg.638]

Morphine antagonists and partial agonists. The effects of opioids can be abolished by the antagonists naloxone or naltrexone (A), irrespective of the receptor type involved. Given by itself, neither has any effect in normal subjects however, in opioid-dependent subjects, both precipitate acute withdrawal signs. Because of its rapid presystemic elimination, naloxone is only suitable for parenteral use. Naltrexone is metabolically more stable and is given orally. Naloxone is effective as antidote in the treatment of opioid-induced respiratory paralysis. Since it is more rapidly eliminated than most opioids, repeated doses may be needed. Naltrexone may be used as an adjunct in withdrawal therapy. [Pg.214]

Respiratory depression Accidental overdose with long-acting opioids (eg, methadone, levomethadyl) may result in prolonged respiratory depression. While nalmefene has a longer duration of action than naloxone in fully reversing doses, be aware that a recurrence of respiratory depression is possible. Observe patients until there is no reasonable risk of recurrent respiratory depression. [Pg.382]

Onset, peak, and duration - Onset of action of IV naloxone is generally apparent within 2 minutes it is only slightly less rapid when given subcutaneously or IM. Duration of action of 1 to 4 hours depends upon dose and route. IM use produces a more prolonged effect than IV use. [Pg.385]

Respiratory depression At the usual adult dose of 10 mg/70 kg, nalbuphine causes respiratory depression approximately equal to that produced by equal doses of morphine. However, nalbuphine exhibits a ceiling effect increases in dosage beyond 30 mg produce no further respiratory depression. Respiratory depression induced by nalbuphine can be reversed by naloxone. Administer nalbuphine with caution at low doses to patients with impaired respiration (eg, from other medication, uremia, bronchial asthma, severe infection, cyanosis, or respiratory obstructions). [Pg.896]

Tablets Administer sublingually as a single daily dose in the range of 12 to 16 mg/day. When taken sublingually, buprenorphine and buprenorphine/naloxone have similar clinical effects and are interchangeable. Buprenorphine tablets contain no naloxone and are preferred for use during induction. Tablets Administer sublingually as a single daily dose in the range of 12 to 16 mg/day. When taken sublingually, buprenorphine and buprenorphine/naloxone have similar clinical effects and are interchangeable. Buprenorphine tablets contain no naloxone and are preferred for use during induction.
Reducing dosage and stopping treatment - Make the decision to discontinue therapy with buprenorphine or buprenorphine/naloxone after a period of maintenance or brief stabilization as part of a comprehensive treatment plan. Gradual and abrupt discontinuation have been used but there is not a best method of tapering the dose at the end of treatment. [Pg.898]


See other pages where Naloxone dosing is mentioned: [Pg.573]    [Pg.362]    [Pg.252]    [Pg.583]    [Pg.573]    [Pg.362]    [Pg.252]    [Pg.583]    [Pg.450]    [Pg.450]    [Pg.383]    [Pg.384]    [Pg.412]    [Pg.78]    [Pg.181]    [Pg.58]    [Pg.81]    [Pg.83]    [Pg.84]    [Pg.85]    [Pg.387]    [Pg.103]    [Pg.96]    [Pg.1017]    [Pg.4]    [Pg.115]    [Pg.144]    [Pg.149]    [Pg.73]    [Pg.316]    [Pg.320]    [Pg.421]    [Pg.18]    [Pg.259]    [Pg.18]   
See also in sourсe #XX -- [ Pg.1098 ]




SEARCH



Naloxon

Naloxone

© 2024 chempedia.info